CSJ137
Total Payments
$92,275
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $33,042 | 1 | 0 |
| 2019 | $34,702 | 1 | 0 |
| 2018 | $13,090 | 1 | 0 |
| 2017 | $11,441 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $92,275 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A FIRST IN HUMAN TWOPART OPEN LABEL AND RANDOMIZED OR DOUBLE BLIND OR PLACEBO CONTROLLED SINGLE DOSE STUDY OF CSJ137 IN ERYTHROPOIETIN TREATED CHRONIC HEMODIALYSIS PATIENTS WITH FUNCTIONAL IRON DEFICIENCY ANEMIA | Novartis Pharmaceuticals Corporation | $92,275 | 0 |
Top Doctors Receiving Payments for CSJ137
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Orlando, FL | $92,275 | 4 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $92,275
- Total Doctors 0
- Transactions 4
About CSJ137
CSJ137 is a drug associated with $92,275 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $33,042 was paid across 1 transactions to 0 doctors.
The most common payment nature for CSJ137 is "Unspecified" ($92,275, 100.0% of total).
CSJ137 is associated with 1 research study, including "A FIRST IN HUMAN TWOPART OPEN LABEL AND RANDOMIZED OR DOUBLE BLIND OR PLACEBO CONTROLLED SINGLE DOSE STUDY OF CSJ137 IN ERYTHROPOIETIN TREATED CHRONIC HEMODIALYSIS PATIENTS WITH FUNCTIONAL IRON DEFICIENCY ANEMIA" ($92,275).